BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2891442)

  • 1. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
    Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
    Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of taxol given as a 3-hour infusion every 21 days.
    Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
    Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
    Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
    Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of taxol in patients with advanced cancer.
    Donehower RC; Rowinsky EK; Grochow LB; Longnecker SM; Ettinger DS
    Cancer Treat Rep; 1987 Dec; 71(12):1171-7. PubMed ID: 2891441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Shepherd FA; Latreille J; Paul K; Eisenhauer E
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
    Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of taxol given by a 6-hour intravenous infusion.
    Brown T; Havlin K; Weiss G; Cagnola J; Koeller J; Kuhn J; Rizzo J; Craig J; Phillips J; Von Hoff D
    J Clin Oncol; 1991 Jul; 9(7):1261-7. PubMed ID: 1675263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):3-8. PubMed ID: 7939760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
    Paccagnella A; Favaretto A; Oniga F; Ossana L
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):76-9. PubMed ID: 9007128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.